Review: Use of continuous subcutaneous insulin infusion in special populations and circumstances in patients with type 1 diabetes

Abstract

CSII (continuous subcutaneous insulin infusion) is a valuable therapeutic option for many patients with type 1 diabetes, specifically where hyperglycaemia or recurrent hypoglycaemia persist during MDI (multiple daily injection) therapy. Special situations under which the use of CSII requires consideration include pregnancy, surgery and exercise. There is no evidence that CSII and MDI therapy differ significantly in efficacy in relation to maternal or foetal outcomes. Accordingly, NICE (National Institute for Health and Clinical Excellence) recommends that pregnant women with insulin-treated diabetes should be offered CSII using the same criteria as the general population. While continuous intravenous insulin infusion may offer advantages over MDI in patients with diabetes undergoing surgery, the role of CSII is unclear. During sports, CSII can facilitate better glycaemic control by allowing the precise adjustment of the basal rate and the administration of small incremental doses, and this may be complemented by the use of CGM (continuous glucose monitoring). More generally, real-time CGM can substantially improve glycaemic control in poorly controlled patients and, using sensor alarms, reduce hyperglycaemia and hypoglycaemia, although the clinical role of this technology is not well defined. Further research should evaluate the potential value of CSII in other populations and clinical scenarios.

Keywords

continuous insulin infusion diabetes mellitus insulin pump pregnancy exercise

Get full access to this article

View all access options for this article.

References

Hoogma RP

Hammond PJ

Gomis R.

et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006; 23:141-7.

Bruttomesso D.

Crazzolara D.

Maran A.

et al. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine . Diabet Med 2008; 25:326-32.

Jakisch BI

Wagner VM

Heidtmann B.

et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med 2008; 25:80-5.

Jeitler K.

Horvath K.

Berghold A.

et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51:941-51.

Pickup JC

Sutton AJ

Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections versus continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-74.

Pickup JC

Renard E.

Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008; 31(suppl 2):S140-5.

National Institute for Health and Clinical Excellence.

NICE technology appraisal guidance 151. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57). London: National Institute for Health and Clinical Excellence, July 2008. http://www.nice.org.uk/TA151 (Accessed 23 July 2008).

National Collaborating Centre for Women's and Children's Health/National Institute for Health and Clinical Excellence.

Clinical guideline. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. London: Royal College of Obstetricians and Gynaecologists, London, March 2008. http://www.nice.org.uk/nicemedia/pdf/CG063FullGuidance.pdf (Accessed 24 May 2008).

Gabbe SG

Carpenter LB

Garrison EA

New strategies for glucose control in patients with type 1 and type 2 diabetes mellitus in pregnancy. Clin Obstet Gynecol 2007; 50:1014-24.

10.

Farrar D.

Tuffnell DJ

West J.

Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007; (3):CD005542.

11.

Mukhopadhyay A.

Farrell T.

Fraser RB

et al. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197:447-56.

12.

Chen R.

Ben-Haroush A.

Weissman-Brenner A.

et al. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 2007 ; 197:404.e1-e5.

13.

Giménez M.

Conget I.

Nicolau J.

et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol 2007; 44:34-7.

14.

Furnary AP

Wu Y.

Bookin SO

Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocr Pract 2004; 10(suppl 2): 21-33.

15.

Vora AC

Saleem TM

Polomano RC

et al. Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes. Endocr Pract 2004; 10:112.

16.

Li JY

Sun S.

Wu SJ

Continuous insulin infusion improves postoperative glucose control in patients with diabetes mellitus undergoing coronary artery bypass surgery. Tex Heart Inst J 2006; 33:445-51.

17.

Admon G.

Weinstein Y.

Falk B.

et al. Exercise with and without an insulin pump among children and adolescents with type 1 diabetes mellitus. Pediatrics 2005; 116:e348-e355.

18.

Diabetes Research in Children Network (DirecNet) Study Group

Tsalikian E.

Kollman C.

et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care 2006; 29:2200-04.

19.

Ludvigsson J.

Hanas R.

Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003; 111(5 Pt 1):933-8.

20.

Tanenberg R.

Bode B.

Lane W.

et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc 2004; 79:1521-6.

21.

Deiss D.

Bolinder J.

Riveline J.

et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29:2730-2.

22.

Bode B.

Gross K.

Rikalo N.

et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol Ther 2004; 6:105-13.

23.

Garg S.

Zisser H.

Schwartz S.

et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006; 29:44-50.

24.

Hanaire H.

Continuous glucose monitoring and external insulin pump: towards a subcutaneous closed loop. Diabetes Metab 2006; 32:534-8.